ADVA
2.6.2020 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Zenlayer is deploying its FSP 3000 technology to provide dynamic, highly available services to some of the world’s biggest gaming, cloud computing and social media companies. The solution will deliver flexible, ultra-low-latency connectivity, enabling the cloud service provider to address huge bandwidth needs as and when required. This is essential for Zenlayer’s customers that require highly resilient services with dynamic capacity. Built on the compact and scalable ADVA FSP 3000 platform , the new network will carry multiple services, including Ethernet, Fibre Channel and SONET/SDH. For maximum efficiency and elasticity, it also features ADVA’s QuadFlex™ line cards and OpenFabric™ cross-connect technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005062/en/
“With this deployment, we’re injecting new levels of flexibility and reliability into our infrastructure. ADVA’s technology offers a major boost to our customers who are delivering more and more data-intensive real-time services to their end users. It opens the door to the next generation of teleconferencing, streaming and online gaming technologies,” said Alex Wang, network architect and product manager, Zenlayer. “Our new solution is extremely efficient in terms of footprint and power consumption. It’s also a future-proof investment ready to scale even further in years to come. Another key component in the success of the project was our close working relationship with ADVA’s engineers. They made sure the whole process was seamless and speedy from network design to shipment and implementation.”
Zenlayer’s new transport network includes some of ADVA’s most innovative technology. Specifically designed for scale and bandwidth optimization, the ADVA FSP 3000 platform ensures that the infrastructure meets the most stringent density and energy demands. Using ADVA FSP 3000 QuadFlex™ technology, the solution delivers outstanding spectral efficiency. The new network also features the ADVA FSP 3000 OpenFabric™ , an OTN cross-connect that creates a distributed architecture, empowering Zenlayer to simply and efficiently adjust bandwidth and turn up new services in an instant. What’s more, for Zenlayer customers such as public cloud and global gaming companies, the solution’s low-latency, high-availability performance will translate directly into end-user satisfaction.
“This deployment will benefit a great number of enterprises operating in Taiwan and Singapore. With the ability to flexibly and efficiently transport multi-traffic services at speeds up to 200Gbit/s, Zenlayer’s telecom, cloud service and gaming customers can enhance the experience of their end users and gain a vital competitive edge,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Zenlayer has a clear vision of what its customers expect and a bold strategy for delivering it. By harnessing our technology and the expertise of our engineers, Zenlayer has created a network ready to adapt to evolving demands and able to expand further in years to come.”
“Our open FSP 3000 technology is the ultimate response to ever-increasing data requirements. It gives Zenlayer the tools it needs to grow its network and develop its edge cloud services in a cost-efficient and highly sustainable way,” said Rocky Weicong Zhou, director, global business development, ADVA. “Combined with our QuadFlex™ and OpenFabric™ technologies, our FSP 3000 platform provides superb levels of capacity and agility. It enables Zenlayer to respond flexibly to huge increases in traffic volume while at the same time making savings on energy use and rack space. With a highly flexible and efficient transport system, Zenlayer can give its enterprise customers world-class connectivity to markets across the globe.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005062/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
